Amyloid dementia

All the drugs to treat Alzheimer, the commonest form of dementia, are useless. As the population ages and goes evermore crazier, the cost of Alzheimer’s care in the U.S. will reach $1 trillion annually by 2050. Biogen with Eisai (a Japanese firm) have an anti-amyloid something that seems to work. Who else works with amyloids, Pfizer? Buy. 

Here is a chance to be a rich Alzie.